A nationwide study of more than 50,000 dogs is generating data no mouse lab can produce. The results so far are changing what researchers know about dementia in both dogs and humans — and pointing to lifestyle factors that owners can act on right now.

Alzheimer's researchers have run thousands of mouse trials. The failure rate tells the story.

Up to 90% of treatments that show promise in mice collapse when tested in humans — a gap that has cost billions and produced almost no breakthroughs. Dogs are structurally different as a research model. Their brains have the same frontal lobe, temporal lobe, and occipital lobe arrangement as a human brain. They develop the same age-related diseases we do: dementia, cancer, joint deterioration, heart conditions. They live in the same homes, breathe the same air, drink the same water, and in many cases eat the same food. And because dogs age faster, researchers can track an entire disease arc in five to ten years instead of sixty to eighty.

That's the premise behind the Dog Aging Project, a collaboration of veterinarians and scientists launched in 2014 by biologist Matt Kaeberlein and colleagues. The project now has more than 50,000 companion dogs enrolled. Owners report on diet, exercise, and living conditions. Researchers collect blood samples and conduct MRIs. When dogs die, their brains are donated, examined, and added to a public database accessible to scientists worldwide. The project has produced more than 50 published studies so far.

The most actionable result the project has produced is also the most cited.

A 2022 analysis of more than 15,000 enrolled dogs found that inactive dogs had six times the odds of developing canine cognitive dysfunction — the dog equivalent of Alzheimer's — compared to very active dogs of the same age, breed, and health status. That's a large effect. It's also observational data built on owner reporting, not a controlled trial. Dogs that are already cognitively declining also tend to exercise less, which means cause and effect are hard to separate. The dementia risk runs in both directions.

What the finding does confirm is that movement and cognitive health are meaningfully connected in dogs — and the magnitude of the association is too large to dismiss. A second finding from the same dataset: dogs living with other dogs showed fewer diseases overall, suggesting that social stimulation plays a role alongside physical activity.

When researchers at Colorado State University examined donated dog brains under a microscope, they found beta-amyloid plaques — the protein deposits that define Alzheimer's in humans — concentrated in dogs showing the most severe cognitive symptoms. The brains looked like human brains with the same disease. That structural similarity is the foundation of the entire research program.

Rapamycin has been on aging researchers' radar for years. In controlled mouse studies, it extended lifespan by as much as 60%. The question was whether the same would hold in dogs.

A pilot study gave rapamycin to six dogs showing signs of cognitive decline; six others received a placebo. When those dogs died and their brains were analyzed, the rapamycin group showed significantly fewer microglial cells — the immune cells that drive brain inflammation and are directly linked to dementia progression. The result held across every treated dog examined.

The larger TRIAD trial — Test of Rapamycin In Aging Dogs — is now enrolling hundreds of dogs across multiple research sites, funded in part by a $7 million NIH grant. Results aren't expected until 2029. A separate biotech company called Loyal has already received FDA sign-off on safety data for a longevity drug targeting dogs over 10, with the stated long-term goal of applying dog data to human aging medicine. The company has raised $250 million.

The Dog Aging Project is producing useful data. It is also working with a significant blind spot.

The 50,000 enrolled dogs eat almost entirely commercial kibble — the diet most companion dogs in America are raised on. Diet type is not a controlled variable in the study. That matters because ultra-processed pet food generates advanced glycation end products, or AGEs, during high-heat manufacturing. AGEs are well-documented drivers of systemic inflammation and cellular aging — the same mechanisms the project is trying to understand and slow. A study that finds strong correlations between lifestyle and cognitive health while leaving diet uncontrolled is measuring an incomplete picture.

The exercise correlation is real and the effect size is meaningful. But a dog that moves daily and eats a high-carbohydrate, heat-processed diet is still accumulating the kind of metabolic burden that accelerates aging at the cellular level. Until the Dog Aging Project stratifies by diet type — raw-fed versus kibble-fed, minimally processed versus ultra-processed — its findings will remain limited in a specific and important way.

Daily exercise is the clearest takeaway the research has produced. Movement is consistently linked to better cognitive outcomes in dogs, and the six-times risk differential is large enough to act on regardless of the study's methodological constraints.

Diet is the variable the project hasn't closed. The rapamycin trials and Loyal's drug pipeline may eventually offer pharmaceutical options, but results are years away. The two levers available today are movement and food quality. Both have more supporting evidence than any drug in a pipeline that won't report results until 2029.

Your dog's brain is aging right now. The researchers will publish their findings later.

KibbleFacts.com All rights reserved. Kibble Facts believes every dog deserves an advocate, and every dog owner deserves clear, trustworthy guidance. From uncovering what’s really in commercial pet food to sharing practical tips on nutrition, wellness, behavior, aging, and the everyday joys of caring for your dog or cat, we’re here to make pet care feel less confusing and a lot more empowering.